Newron Pharmaceuticals (NWRN)

Business description

Newron is a CNS-focused biotech. Xadago (partnered with Zambon, US WorldMeds, Meiji Seika, Sequirus) for PD has been launched in Europe and the US. Other pipeline assets include Sarizotan (Phase III for RS) and Evenamide (Phase II for schizophrenia).

Xadago launches in Germany

Update | Pharmaceutical & healthcare | 20/05/2015

Xadago has been launched in Germany as expected by commercial partner Zambon, which should lead to Newron’s first recurring royalty income. Xadago has been priced at a premium to Azilect in Germany, which if replicated in other countries and regions, could suggest upside potential to our current forecasts and valuation. We continue to expect a Xadago US approval decision by YE15. Our valuation and forecasts have been updated to reflect the CHF24.3m fund-raise, with our valuation CHF526m.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.CHF163.2m
Last closeCHF9.150
High / Low (52 weeks)CHF27.7 / CHF8.8
Stock market listingSW
Forecast net cash (€m)63.2
Forecast gearing ratio (%)N/A
SectorPharmaceutical & healthcare

Price performance

Relative *(10.4)(9.9)(67.3)

* % Relative to local index

Company news

Newron Pharmaceuticals

Thu, 08 Feb 2018 18:37:38 GMT

Newron Pharmaceuticals

Tue, 06 Feb 2018 12:00:00 GMT

Newron Pharmaceuticals

Wed, 25 Oct 2017 10:52:30 GMT

Newron Pharmaceuticals

Wed, 17 May 2017 04:52:30 GMT

Newron Pharmaceuticals

Mon, 24 Oct 2016 14:00:33 GMT